Desonide foam: A review

Drugs of Today

Volumn 44, Issue 1, 2008, Pages 55-62

  Parish, Daniel ^a   Scheinfeld, Noah ^b,c  

^a PENNSYLVANIA HOSPITAL   (United States)

^b Department of Medicine   (United States)

^c Department of Dermatology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE DIPROPIONATE; AMCINONIDE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; DESONIDE; DESOXIMETASONE; DIFLORASONE DIACETATE; FLUDROXYCORTIDE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; HALCINONIDE; HYDROCORTISONE BUTYRATE; HYDROCORTISONE VALERATE; MOMETASONE FUROATE; PLACEBO; PREDNICARBATE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; ULOBETASOL PROPIONATE;

ANTIINFLAMMATORY ACTIVITY; APPLICATION SITE ATROPHY; APPLICATION SITE BURNING; APPLICATION SITE DERMATITIS; APPLICATION SITE IRRITATION; APPLICATION SITE REACTION; ASTHMA; ATOPIC DERMATITIS; BLOOD PRESSURE; CHEMICAL MUTAGENESIS; CONTACT DERMATITIS; COUGHING; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CARCINOGENICITY; DRUG EFFICACY; DRUG FORMULARY; DRUG FORMULATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FOAM; HEADACHE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFERTILITY; IRRITABILITY; NONHUMAN; PHARYNGITIS; REVIEW; SIDE EFFECT; TELANGIECTASIA; TERATOGENICITY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; CHILD; DERMATITIS, ATOPIC; DESONIDE; HUMANS; VEHICLES;

EID: 40849094386     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.1.1143847     Document Type: Review

References (27)

1. Hughes, J., Rustin, M. Corticosteroids. Clinics in Dermatol 1997, 15: 715-21.
2. Norris, D. Mechanisms of action of topical therapies and the rationale for combination therapy. Journal of the American Academy of Dermatology 2005, 53(1): S17-S25.
3. Henge, U., Ruzicka, T., Schwartz, R., Cork, M. Adverse effects of topical glucocorticosteroids. Journal of the American Academy of Dermatolog 2006, 54: 1-15.
4. Wolkerstorfer A., De Waard V.R., van der Spek, F.B., Mulder, P.G., Oranje, A.P. Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution. The British journal of dermatology 2000, 105: 794-9.
5. Jorizzo, J., Levy, M., Lucky, A. et al. Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology 1995, 33(1): 74-7.
6. Cornell, R., Baker, M. Dermal safety comparison of 0.05% desonide cream and 1% hydrocortisone cream. Curr Ther Res 1993, 53: 356-9.
7. Freeman, S., Howard, A., Foley, P. et al. Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis. The Australasian journal of dermatology 2002, 43(3): 186-9.
8. Hebert, A.A., Cook-Bolden, F.E., Basu, S., Calvarese, B., Trancik, R.J. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol 2007, 6(2): 175-81.
9. Bluefarb, S.M. Clinical comparison of desonide cream with betamethasone valerate cream. A double-blind randomized study. International journal of dermatology 1972, 11(2): 73-6.
10. Reque, P.G. The treatment of common dermatoses with topically applied 0.05 per cent desonide cream. A paired-comparison clinical study. Journal of the Medical Association of the State of Alabama 1972, 42(1): 25-7.
11. Donsky, H. A comparative double-blind randomized clinical study of a new, non-fluorinated topical corticosteroid. Cutis; cutaneous medicine for the practitioner 1972, 9: 46-8.
12. Smith, E.B., Gregory, J.F., Bartruf,f J.K. Desonide, a potent nonfluorinated topical steroid, vasoconstriction assay and clinical trial. Southern medical journal 1973, 66(3): 325-9.
13. Barsky, S. Clinical comparison of desonide cream with fluocinonide cream in steroid-responsive dermatologic disorders. Cutis; cutaneous medicine for the practitioner 1976, 18(6): 826-30.
14. Gentry, W.C. Jr., Rosenberg, E.W., Goltz, R.W. A clinical evaluation of 0.05 per cent desonide cream. A new nonfluorinated topical corticosteroid. Archives of dermatology 1973, 107(6): 870-1.
15. Greenspan, A., Herndon, J., Baker, M., Cheney, T. Controlled evaluation of 0.05% desonide lotion and desonide cream in psoriasis. Cur Ther Resr 1993, 53(6): 614-9.
16. Frost, P., Horwitz, S.N. Clinical comparison of alclometasone dipropionate and desonide ointments (0.05%) in the management of psoriasis. The Journal of international medical research 1982, 10(5): 375-8.
17. Grimalt, R., Mengeaud, V., Cambazard, F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: A randomized controlled study. Dermatol Surg 2007, 214: 61-7.
18. Henrijean, A., Lapiere, C. Clinical evaluation of desonide cream. Curr Ther Res 1983, 33: 775-81.
19. Lebrun-Vignes, B., Legrain, V., Amoric, J., Taieb, A. Comparative study of efficacy and effect on plasma cortisol levels of micronised desonide cream 0.1 p. 100 versus betamethasone dipropionate cream 0.05 p. 100 In the treatment of childhood atopic dermatitis. Annales de dermatologie et de venereologie 2000, 127(6-7): 590-5.
20. Weaver, J. Summary of adverse events in pediatric patients (PID-D010141): FDA; July 9, 2001.
21. Wong, V.K., Fuchs, B., Lebwohl, M. Overview on desonide 0.05%: a clinical safety profile. J Drugs Dermatol 2004, 3(4): 393-7.
22. Bhankharia, D., Sanjana, P. Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: A post-marketing surveillance study. Indian J Dermatol Venereol Leprol 2004, 70: 288-91.
23. Karwoski, C. Postmarketing safety review of topical corticosteroids: adrenal insufficiency, Cushing's syndrome, and growth retardation in pediatric patients (PID D030565) September 26, 2003.
24. Lucky, A.W., Grote, G.D., Williams, J.L. et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis; cutaneous medicine for the practitioner. Mar 1997, 59(3): 151-3.
25. Hernandez, N., Assier-Bonnet, H., Terki, N., Revuz, J. Allergic contact dermatitis from propyl gallate in desonide cream (Locapred). Contact dermatitis. Feb 1997, 36(2): 111.
26. Sturtz, R.P., Rau, R.C. Contact dermatitis to desonide. Archives of dermatology. Dec 1983, 119(12): 1023.
27. Garner, L.A., Cruz, P.D. Jr. Contact puzzle: Worsening of a recurrent facial eruption despite treatment. Diagnosis: allergic contact dermatitis caused by desonide. Am J Contact Dermat 1999, 10(2): 81-2.